Under construction – not a live service
Sign in
Taking people in DenmarkNo phase

Magnetic stimulation of the brain to ease fatigue in multiple sclerosis

Tests magnetic brain stimulation against sham stimulation for fatigue in multiple sclerosis.

Plain-language title generated from the registry record
Registry title: Fatigue Alleviation Through Neuromodulating Therapy in Multiple Sclerosis

Key facts

Where
Hvidovre, DenmarkSee the site

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Source: NCT06569550, who can take part

Where in Denmark

  • Danish Research Centre for Magnetic ResonanceHvidovre, DenmarkTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Danish Research Centre for Magnetic Resonance
Trial code
NCT06569550
Record updated
22 September 2026
Original description
The goal of this clinical trial is to learn if repetitive Transcranial Magnetic Stimulation (rTMS) of the left premotor cortex can lessen fatigue in patients with Multiple Sclerosis, and if this is a feasible intervention. It will also give further information on fatigue in Multiple Sclerosis. The main questions it aims to answer is:Read full original descriptionShow less

Neuromodulation of the Left Premotor Cortex With Transcranial Magnetic Stimulation to Alleviate Fatigue in Multiple Sclerosis - a Randomised Controlled Clinical Trial

The goal of this clinical trial is to learn if repetitive Transcranial Magnetic Stimulation (rTMS) of the left premotor cortex can lessen fatigue in patients with Multiple Sclerosis, and if this is a feasible intervention. It will also give further information on fatigue in Multiple Sclerosis. The main questions it aims to answer is:

* Does premotor rTMS decrease fatigue symptoms in patients with Multiple Sclerosis? * Is the change in fatigue reflected in an altered balance between brain excitation and inhibition in the targeted premotor cortex?

Researchers will compare real rTMS with sham rTMS (which does not stimulate with a magnetic field), to see if real rTMS works to alleviate fatigue.

Participants will:

* Receive real or sham rTMS for 30 minutes, 5 days in a row * Visit the clinic before and 6 days after for baseline and follow-up * Fill out on-line questionnaires 1 day and 4 weeks after the end of intervention * Undergo a total of 3 brain scans (Magnetic Resonance Imaging at ultra-high field), at baseline, end of intervention, and follow-up * Undergo lab neurophysiological measurements before and after the first intervention session * Keep a fatigue diary and wear an activity tracker in the period before and after the intervention

Inclusion: A confirmed diagnosis of relapse-remitting or secondary progressive multiple sclerosis, according to most recent McDonald's criteria (Thompson et al., 2018). This diagnosis must not be more recent than 3 months; Must have fatigue as a complaint, and an FSMC score corresponding to at least moderate fatigue (>53); Stable MS medication for at least 3 months.

Exclusion: MS Relapse or steroid treatment within 3 months prior to inclusion; Current treatment targeted towards fatigue, or previous if discontinued within 3 months prior to inclusion; Intake of medication that primarily acts on CNS or neurotransmission, except SSRI or SNRI; Any metallic implant incompatible with MR scanning; Current Drug or alcohol abuse; History of neurologic disease or other significant medical conditions, aside from MS; Major psychiatric disorder, including current clinical depression; Either patient or their close relatives suffering from epilepsy; Pregnancy, any subject with the potential to become pregnant must ensure against this (e.g. by taking oral contraceptives, or other high efficacy method); EDSS > 6.5; Pacemaker or other implanted electronic devices; Any intracranial metal; Claustrophobia.

ClinicalTrials.gov NCT06569550